Now that Prostvac has failed as a stand-alone therapy, Bavarian Nordic's MVA-BN RSV vaccine is now extra-important.
Here is some other vaccine news of note for the week.
Merck and GSK are coping with hepatitis A vaccine shortages as the U.S. is experiencing deadly outbreaks.
Dynavax has completed the long road to approval for its hepatitis B vaccine Heplisav-B.
Egg-based production dampened the effects of last year's flu vaccine, a new study says. What's worse, the problem could repeat this year.
Here is some other vaccine news of note for this week.
Takeda's dengue vaccine induced sustained antibody responses in children, topline phase 2 data showed.
Hoping the world's first dengue vaccine would finally ramp up this quarter? Think again. Luckily for Sanofi, its other shots are doing far better.
Merck's star HPV vaccine missed sales expectations in the third quarter as the company had to borrow from the CDC stockpile to fulfill orders.